Dear Spiral user, We’re pleased to introduce Helix, https://helix.imperial.ac.uk/ Imperial’s new repository for research datasets. Please use Helix for all future dataset deposits. There is no change to Spiral - continue depositing as usual. For queries, contact the Research Data Management team at rdm-enquiries@imperial.ac.uk. Kind regards, the Spiral Team. The Spiral team
The role of precision medicine in interstitial lung disease
File(s)
2102146.full.pdf (435.21 KB)
Published version
Author(s)
Maher, Toby M
Nambiar, Anoop M
Wells, Athol U
Type
Journal Article
Abstract
The management of interstitial lung disease (ILD) may benefit from a conceptual shift. Increased understanding of this complex and heterogeneous group of disorders over the past 20 years has highlighted the need for individualised treatment strategies that encompass diagnostic classification and disease behaviour. Biomarker-based approaches to precision medicine hold the greatest promise. Robust, large-scale biomarker-based technologies supporting ILD diagnosis have been developed, and future applications relating to staging, prognosis and assessment of treatment response are emerging. Artificial intelligence may redefine our ability to base prognostic evaluation on both diagnosis and underlying disease processes, sharpening individualised treatment algorithms to a level not previously achieved. Compared with therapeutic areas such as oncology, precision medicine in ILD is still in its infancy. However, the heterogeneous nature of ILD suggests that many relevant molecular, environmental and behavioural targets may serve as useful biomarkers if we are willing to invest in their identification and validation.
Date Issued
2022-09-01
Date Acceptance
2022-01-12
Citation
European Respiratory Journal, 2022, 60 (3)
URI
DOI
ISSN
0903-1936
Publisher
European Respiratory Society
Journal / Book Title
European Respiratory Journal
Volume
60
Issue
3
Copyright Statement
©The authors 2022.
This version is distributed under
the terms of the Creative
Commons Attribution
Non-Commercial Licence 4.0.
For commercial reproduction
rights and permissions contact
permissions@ersnet.org
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/35115344
PII: 13993003.02146-2021
Publication Status
Published
Coverage Spatial
England
Article Number
ARTN 2102146
Date Publish Online
2022-02-03